MASH with Fibrosis Study
Join us to explore the safety and comfort of a new treatment for people with known or suspected MASH and fibrosis stages F2 or F3.
Study site: NeoClinical Research
- Fatty liver disease (MASH/NASH)
Recruiting
Male/Female
18 - 75 years of age
TBD
- About the Study
- This study aims to evaluate how safe and well-tolerated a new treatment is for those with known or suspected MASH and fibrosis at stages F2 or F3.
- What does the study involve?
- Participants will receive either the new treatment or a placebo (a harmless substitute) to compare results.
What to expect
- Placebo
- You may receive a placebo (a look-alike with no active medicine).
- Which treatment you get
- Chosen at random. Neither you nor the study team will know which treatment you get.
- Who can participate?
- We're looking for adults aged 18–75 who have a history of metabolic syndrome and known or suspected MASH with fibrosis. Some health conditions may disqualify you. Think you might qualify? Apply to find out!
Where is the study taking place?
Palmetto Medical Plaza
Study details
- Sponsor
- GlaxoSmithKline
- Phase
- Phase 3: confirming it works in a large group, often against current treatment
- Dates
- December 2025 to March 2028 (expected)
- Size
- 1250 participants across all sites
- Healthy volunteers
- Only people with the condition
Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
One moment…
About NeoClinical Research
NeoClinical Research is a leading, multi-therapeutic clinical research center based in South Florida that bridges the gap between leading pharmaceutical companies and diverse patient populations.